Phonak EON Brings New AI and Auracast Features to Prescription Hearing Care
Phonak has introduced EON, a new prescription hearing-aid platform that combines AI-based sound processing, universal wireless connectivity, Auracast broadcast audio and rechargeable receiver-in-canal designs. The launch is important industry news because it shows where a major prescription brand is investing: automatic listening-scene management, speech-in-noise performance, connectivity and easier daily use.
It is equally important to interpret the announcement in the correct market context. Phonak EON is a professionally fitted prescription family. Tomore focuses on OTC hearing aids and OEM/ODM solutions. The two categories can learn from the same technology trends, but they differ in intended users, fitting pathways, product claims and regulatory requirements.
What Phonak has introduced
Phonak’s current EON portfolio includes Audéo EON Sphere, Audéo EON R and CROS EON. According to the manufacturer, the family uses its new HYPERSONIC chip and AutoSense OS AI 8.0, while the Sphere model adds Spheric Speech Clarity 3.0 for speech in challenging noise.
The company positions EON as a prescription platform for a wide range of hearing needs. Exact suitability, available features and fitting options depend on the selected model and the individual assessment completed by a hearing-care professional.
The EON product family
Audéo EON Sphere is the flagship model in the family. Phonak states that it is intended for mild-to-profound hearing loss and combines its scene-classification system with a dedicated speech-in-noise technology. Audéo EON R also covers a broad range of hearing loss and uses AutoSense OS AI 8.0 without the Sphere-specific processing listed for the flagship model.
CROS EON is designed for people with unaidable hearing loss in one ear and works with a compatible Audéo EON R device on the other side. This is a specialized professional pathway, not an OTC use case.
AI processing remains the headline
Phonak describes AutoSense OS AI 8.0 as a system that classifies the listening environment and coordinates features for speech in noise, soft speech, movement and wind. Its professional materials also describe Spheric Speech Clarity 3.0 as a dedicated approach for clearer speech in busy environments.
These are manufacturer claims tied to the EON products and Phonak’s own supporting evidence. They should not be generalized to all “AI hearing aids.” AI is a broad label: different devices may use machine learning for scene classification, speech enhancement, fitting recommendations or App functions. Buyers and consumers should look at the exact feature, model and test condition rather than relying on the word AI alone.
Connectivity expands beyond conventional Bluetooth
EON supports Phonak’s Made For All connectivity approach for compatible Bluetooth devices. The platform also adds Auracast broadcast audio, a Bluetooth capability that can transmit sound from participating public or shared systems directly to compatible hearing devices.
Potential use cases include theaters, museums, places of worship, meeting spaces and public information systems. Actual access depends on the venue having an Auracast transmitter, device compatibility and correct user setup. Auracast is growing, but availability is not yet universal.
The EON family also connects with Phonak’s Roger wireless-microphone ecosystem. Together, these options show that connectivity is moving from simple phone streaming toward a wider listening network.
Rechargeability and daily-use design
Phonak lists rechargeable RIC designs and several charging options for the EON family. The manufacturer states that Audéo EON R can provide up to 38 hours of battery life on a full charge, while noting that actual runtime depends on battery condition, hearing loss, sound classification, streaming and activated features.
That qualification matters. Runtime should always be read together with its test conditions. Streaming, wireless accessories, demanding processing and battery age can change real-world results.
Phonak also highlights EasyGuard domes as a maintenance feature and offers the myPhonak App for compatible models. These details reflect a wider industry focus on making advanced technology easier to charge, clean, adjust and support.
Prescription and OTC hearing aids serve different pathways
Under the U.S. Food and Drug Administration’s framework, OTC hearing aids are intended for adults age 18 or older with perceived mild-to-moderate hearing loss. They can be purchased without a prescription, medical examination or mandatory fitting by a licensed professional.
A prescription hearing aid is any hearing aid that does not meet the OTC definition. Prescription devices are obtained through a licensed hearing-care professional, can be programmed to an individual hearing loss and may be appropriate for broader ages and degrees of hearing loss depending on their indications.
That means Phonak EON and Tomore OTC products should not be treated as direct one-to-one alternatives. They address different purchase journeys and may serve different hearing needs. Consumers with severe or profound hearing loss, sudden changes, one-sided hearing problems, pain, drainage, dizziness or other warning signs should seek professional care rather than self-select an OTC device.
What the launch signals for OTC brands
The useful lesson is not that every OTC product must copy a prescription flagship. Instead, EON highlights four expectations spreading across the hearing market.
- Automatic adaptation: Users increasingly expect devices to respond to changing environments with fewer manual adjustments.
- Speech in noise: Busy conversations remain a central user problem and a key area for clear, evidence-based communication.
- Broader connectivity: Bluetooth streaming is becoming a foundation, while broadcast audio creates new future use cases.
- Practical ownership: Charging, cleaning, App usability and support are part of product value—not afterthoughts.
For OTC and private-label brands, the opportunity is to translate those expectations into features appropriate to the intended user, price point and regulatory category.
Keep comparisons accurate
Industry reporting often compresses a complex platform into a few impressive figures. Responsible analysis should identify whether a number comes from the manufacturer, an internal study or independent research. It should also preserve the tested device, fitting, population, listening condition and comparison.
Tomore does not claim that its current OTC products use Phonak’s AI platform, HYPERSONIC chip, Spheric Speech Clarity, AutoSense OS or other proprietary Phonak technologies. Mentioning the launch is market analysis, not a claim of technical equivalence.
The broader industry takeaway
Phonak EON shows how the prescription segment is combining sound processing, professional fitting, connectivity and rechargeable daily use in one platform. It also reinforces an important market pattern: advanced features need a clearly defined user, fitting pathway and evidence base.
The prescription and OTC sectors do not need to be identical to influence one another. Prescription launches can reveal changing consumer expectations, while OTC products can focus on accessible purchasing, understandable controls and suitable support for adults with perceived mild-to-moderate hearing loss.
For Tomore’s OEM and ODM partners, the practical question is how to build the right feature set for the intended OTC audience—without borrowing prescription claims that do not belong to the product. Contact Tomore to discuss digital processing, connectivity, rechargeable formats and model-specific private-label requirements.